Similar Papers

Paper Title
Journal
Date
Author
Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104).
...
Journal of Clinical Oncology | VOL. 35
, et. al. ...
20 May 2017
Cost-effectiveness analysis of atezolizumab as adjuvant treatment of patients with stage II-IIIA non-small cell lung cancer, PD-L1+≥50% of tumor cells in France: A modeling study
Ingrid Plessala ... Christos Chouaid
Lung Cancer | VOL. 184
Ingrid Plessala, et. al.Ingrid Plessala ... Christos Chouaid
26 Jul 2023
Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing ≥50% PD-L1: A United Kingdom health care perspective
Chui-Ying Yip ... Nick Jovanoski
Lung Cancer | VOL. 179
Chui-Ying Yip, et. al.Chui-Ying Yip ... Nick Jovanoski
15 Mar 2023
Efficacy and safety of aumolertinib combined with or without chemotherapy as an adjuvant treatment for stage II-IIIA non-small cell lung cancer following complete tumour resection: The first third-generation EGFR-TKI versus chemotherapy phase III clinical study (APEX).
Feng Tan ... Yongtao Han
Journal of Clinical Oncology | VOL. 42
Feng Tan, et. al.Feng Tan ... Yongtao Han
01 Jun 2024
View more papers

More From: Value in Health

Paper Title
Journal
Date
Author
Table of Contents
-
Value in Health | VOL. 28
--
01 Feb 2025
Cost-effectiveness of a digitally supported care management program for caregivers of people with dementia
Michelle Pfaff ... Bernhard Michalowsky
Value in Health | VOL. -
Michelle Pfaff, et. al.Michelle Pfaff ... Bernhard Michalowsky
01 Feb 2025
Editorial Board
-
Value in Health | VOL. 28
--
01 Feb 2025
How do individuals value worse-than-dead EQ-5D-5L health states in composite time trade-off tasks? A qualitative study
Meixia Liao ... Nan Luo
Value in Health | VOL. -
Meixia Liao, et. al.Meixia Liao ... Nan Luo
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.